Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rojer Ranjit"'
Autor:
Krishna Gunturu, Muhammad Awidi, Rojer Ranjit, Brendan Connell, Rachel Carrasquillo, Brigitte Gil, Natalie Dalbo, Lewena Maher, Seanna Reilly, Stephanie McDonald, Philip Tsoukas, Linda Voner
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/9e9b736f66324779841dc45c97d0d05c
Autor:
Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:2375-2382
Background The use of immune checkpoint inhibitors (ICI) has transformed cancer treatment. Subsequent ICI use has become increasingly common following disease progression. We aim to evaluate the safety and tolerability of the sequential ICI treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e45e0576af4cac7825e730823fd9ff
https://doi.org/10.1007/s00432-022-04137-4
https://doi.org/10.1007/s00432-022-04137-4
Autor:
Stephanie McDonald, Seanna Reilly, Linda Voner, Rachel Carrasquillo, Muhammad Awidi, Brendan James Connell, Brigitte Gil, Philip Tsoukas, Lewena Maher, Rojer Ranjit, Krishna S Gunturu, Natalie Dalbo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background ICI revolutionized modern Oncology landscape and being utilized in metastatic to adjuvant and neo-adjuvant settings. As Oncologists, we are treating cancer patients with ICI every day, yet there is still a lot that is unknown about these d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fedd4ee8e44bee4241d707afa04cb8a9
https://doaj.org/article/9e9b736f66324779841dc45c97d0d05c
https://doaj.org/article/9e9b736f66324779841dc45c97d0d05c
Autor:
Krishna S Gunturu, Philip Tsoukas, Seanna Daves, Muhammad Awidi, Rojer Ranjit, Stephanie McDonald, Brendan James Connell, Linda Voner, Natalie Dalbo, Lewena Maher, Brigitte Gil
Publikováno v:
Journal of Clinical Oncology. 39:e18835-e18835
e18835 Background: Immune checkpoint inhibitors (ICI) up regulate T cell activity promoting tumor cell death and revolutionized modern oncology. The use and number of indications for ICI is growing at an unprecedented speed. Combination and sequentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::566dac9969c2026f878b9fe8ed1315fa
https://doi.org/10.1200/jco.2021.39.15_suppl.e18835
https://doi.org/10.1200/jco.2021.39.15_suppl.e18835